Dezima, Amgen deal

Amgen will acquire Dezima for $300 million up front and up to $1.3 billion in milestones, plus low single-digit royalties. Amgen will acquire TA-8995, a cholesteryl ester transfer protein (CETP) inhibitor that has completed Phase IIb testing to treat dyslipidemia. ...